Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20773759 | 1.00 | HCRTR1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL28647414 | 0.72 | HCRTR1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL19256191 | 0.72 | HCRTR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL19256193 | 0.72 | HCRTR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL19256194 | 0.72 | HCRTR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL7912880 | 0.72 | HCRTR1 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL31336948 | 0.71 | HCRTR1 (0.37) | HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL31372558 | 0.71 | HCRTR1 (0.35) | HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL31372680 | 0.71 | HCRTR1 (0.35) | HCRTR1HCRTR2 | |
| Bromide SCHEMBL19207060 | 0.71 | HCRTR1 (0.43) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.